End stage renal disease
Drug research and approvals for end stage renal disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 168 studies of end stage renal disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, and FDA has 3 approved and 13 open orphan designations naming it.
- Recruiting worldwide: 168
- Trials authorized in Canada: 9
- FDA orphan approvals: 3
- EU medicines: 0
- Six-Channel Wearable ECG for Prediction of Hyperkalemia in Hemodialysis PatientsNCT07947485 · Not reported · Chungnam National University Hospital · starts Nov 12, 2026
- Nurse-Led Interventions Addressing Physical Exercise and Psychological Needs on Enhancing Outcomes in Patients With…NCT07927660 · Not applicable · Menoufia University · starts Feb 1, 2026
- A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney…NCT07916181 · Phase 1 · Basilea Pharmaceutica · starts Oct 27, 2026
- Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot TrialNCT07910773 · Not applicable · University of California, San Francisco · starts Oct 30, 2026
- Physical Exercise in Patients With Chronic Kidney Disease in Hemodialysis (Pehedal-ESKD)NCT07820514 · Not applicable · Ricerca Nefrocenter · starts Jun 1, 2024
- A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of RibupatideNCT07793929 · Phase 1 · Kailera · starts Sep 8, 2026
- Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to TransplantationNCT07792317 · Not applicable · Vivalyx GmbH · starts Nov 17, 2025
- Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis…NCT07781124 · Not reported · Vantive Health LLC · starts Jun 17, 2026
- LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous GraftNCT07773051 · Not applicable · Longhua Hospital · starts Aug 25, 2025
How its trials ended
1,934 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 398 whose ending is known, 42% met their primary endpoint, 8% missed it and 50% stopped early.
- Completed, result not reported98351%
- Status unknown29315%
- Ongoing26013%
- Met its primary endpoint1679%
- Stopped: other or unclear1146%
- Stopped: enrollment or feasibility462%
- Missed its primary endpoint312%
- Stopped: sponsor or business decision151%
- Stopped: funding131%
- Stopped: lack of efficacy101%
- Stopped: safety2<1%
| May 30, 2025 | Effect of canagliflozin on ultrafiltration & fibrosis in patients on peritoneal dialysis (can-pd trial)Canagliflozin | Research Institute of The McGill University Health Centre | Pending |
| Jun 12, 2024 | Evaluation of thiosulfate in end stage renal disease and kidney transplantationSodium thiosulfate | London Health Sciences Centre | Ongoing |
| Apr 5, 2023 | The efficacy, mechanism & safety of sodium glucose co-transporter-2 inhibitor & glucagon-like peptide 1 receptor agonist combination therapy in kidney…Dapagliflozin/ Semaglutide | University Health Network | Ongoing |
| Jan 4, 2023 | Mechanisms and safety of SGLT2 inhibition in peritoneal dialysis - the canary studyEmpagliflozin | University Health Network | Pending |
| Jun 15, 2022 | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center phase 2 clinical outcome trial of prevention of arteriovenous graft…MK-2060 | Merck & Co. (MSD) | Ongoing |
| Apr 10, 2017 | Aldosterone blockade for health improvement evaluation in end-stage renal disease (ACHIEVE)Spironolactone | Population Health Research Institute | Closed |
| Feb 19, 2016 | Pharmacokinetics and pharmacodynamics of apixaban in end-stage renal disease patients on hemodialysisApixaban | Jewish General Hospital | Closed |
| Aug 11, 2015 | A phase 2, randomized, double blind, placebo controlled study of the safety, pharmacokinetics, and pharmacodynamics of multiple doses of isis 416858…Isis 416858 | Ionis Pharmaceuticals | Closed |
| May 30, 2014 | A pilot study to evaluate the feasibility and safety of performing a double blind, placebo-controlled, randomized controlled trial of the routine use of ssri's…Escitalopram | University Health Network | Ongoing |
| Dec 20, 2002 | Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis SolutioFor use as a single daily exchange for the long (8-16 hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated… | Baxter Healthcare Corporation | Approved |
| Dec 15, 1999 | CarnitorPrevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. | Leadiant Biosciences, Inc. | Approved |
| Jun 1, 1989 | EpogenTreatment of anemia associated with chronic renal failure, including patients on dialysis (end stage renal disesae) and patients not on… | Amgen, Inc. | Approved |
| Nov 9, 2020 | Peritoneal dialysis solution containing combination of…Treatment of patients with end stage renal disease who are undergoing peritoneal dialysis | CoreQuest Sagl | Designated |
| Mar 7, 2019 | TecarfarinPrevention of systemic thromboembolism of cardiac origin in patients with End Stage Renal Disease and atrial fibrillation | Cadrenal Therapeutics, Inc. | Designated |
| Feb 21, 2019 | Peritoneal dialysis solution containing combination of…Treatment of patients with end stage renal disease who require peritoneal dialysis | CoreQuest Sagl | Designated |
| Nov 6, 2017 | Alanyl-glutamine dipeptidePrevention of complications associated with peritoneal dialysis (PD) treatment in end stage renal disease (ESRD) | Zytoprotec GmbH | Designated |
| Jun 15, 2017 | Human monoclonal antibody against phosphorylcholinePrevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or… | Athera Biotechnologies, AB | Designated |
| May 10, 2012 | Sirolimus in an implantable collagen matrixPrevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing… | SiraNex Bio, LLC | Designated |
| Jun 6, 1990 | Calcium carbonateTreatment of hyperphosphatemia in patients with end stage renal disease. | R & D Laboratories, Inc. | Designated |
| Jun 27, 1989 | Calcium acetateTreatment of hyperphosphatemia in end stage renal disease. | Pharmedic Company | Designated |
| Nov 19, 1987 | Erythropoietin (human, recombinant)Treatment of anemia associated with end stage renal disease. | Organon Teknika Corporation | Designated |
| Oct 22, 1987 | Epoetin betaTreatment of anemia associated with end stage renal disease. | Chugai-USA, Inc. | Designated |
| Aug 27, 1987 | Epoetin alphaTreatment of anemia associated with end stage renal disease. | R. W. Johnson Pharmaceutical Research Institute | Designated |
| Aug 19, 1987 | Erythropoietin (recombinant human)Treatment of anemia associated with end stage renal disease. | McDonnell Douglas Corp | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA